ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Clinical trial NCT02787369 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02787369
- Sponsor
- Dana-Farber Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-05-01
- Primary completion
- 2026-04-01
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.